¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"duck virus hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • occult virus
    ÀáÀç¹ÙÀÌ·¯½º
  • oncogenic virus
    Á¾¾ç¹ß»ý¹ÙÀÌ·¯½º
  • orphan virus
    °í¾Æ¹ÙÀÌ·¯½º
  • parainfluenza virus
    ÆÄ¶óÀÎÇ÷翣ÀÚ¹ÙÀÌ·¯½º
  • passenger virus
    Àϰú¼º¹ÙÀÌ·¯½º, ³ª±×³×¹ÙÀÌ·¯½º
  • respiratory syncytial virus
    È£Èí±â¼¼Æ÷À¶ÇÕ¹ÙÀÌ·¯½º
  • RNA virus
    RNA¹ÙÀÌ·¯½º
  • street virus
    °Å¸®¹ÙÀÌ·¯½º, ¾ß»ý±¤°ßº´¹ÙÀÌ·¯½º
  • simian virus
    ¿ø¼þÀ̹ÙÀÌ·¯½º
  • slow virus
    ½½·Î¿ì¹ÙÀÌ·¯½º
  • virus
    ¹ÙÀÌ·¯½º
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • varicella-zoster virus
    ¼öµÎ´ë»óÆ÷Áø¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Coxsackie virus
    ÄÛ»èŰ¹ÙÀÌ·¯½º(¼Ó).
  • Coxsackie virus
    ÄÛ»èŰ¹ÙÀÌ·¯½º.
  • Coxsackie virus infection
    ÄÛ»èŰ¹ÙÀÌ·¯½º°¨¿°.
  • Cremean hemorrhagic fever virus
    Å©¸®¹Ì¾Æ ÃâÇ÷¿­¹ÙÀÌ·¯½º
  • DNA oncogenic virus
    DNA Á¾¾ç¹ÙÀÌ·¯½º
  • DNA virus
    DNA¹ÙÀÌ·¯½º
  • DNA oncogenic virus
    DNA Á¾¾ç¹ÙÀÌ·¯½º
  • DNA virus
    DNA ¹ÙÀÌ·¯½º
  • DNA-containing virus
    DNA(Æ÷ÇÔ)¹ÙÀÌ·¯½º.
  • Dengue virus
    µ­±â ¹ÙÀÌ·¯½º
  • EB virus
    EB¹ÙÀÌ·¯½º
  • ECHO virus =enteric cytopathogenic dog or p han v.
    ¿¡ÄÚ¹ÙÀÌ·¯½º.
  • ECHO virus =enteric cytopathogenic human orphan v.
    ¿¡ÄÚ¹ÙÀÌ·¯½º(¼Ó).
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • hepatitis,non-a, non-b
    non-A, non-B
  • hepatitis,type a
    A Çü
  • hepatitis,type b
    B Çü
  • infantile hepatitis
    ¿µ¾Æ°£¿°.
  • infectious hepatitis
    Àü¿°¼º °£¿°(îîæøàõÊÜæú).
  • infectious hepatitis
    Àü¿°¼º °£¿°, AÇü°£¿°
  • lupoid hepatitis
    ·çÆ÷À̵尣¿°, ³¶Ã¢¾ç°£¿°(¡­ÊÜæú).
  • lupoid hepatitis
    ·çÆ÷À̵尣¿°, ³¶Ã¢¾ç°£¿°(³¶Ã¢¾çÊÜæú)
  • lupus hepatitis
    ·çǪ½º°£¿°
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°¼º°£¿°(ËíËôËøËçËÛ˧Ëç).
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°¼º °£¿°(éÚêáîîæøàõÊÜæú).
  • mouse hepatitis
    ¸¶¿ì½º°£¿°(¡­ÊÜæú).
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°(~ÊÜæú).
  • non-A, non-B, hepatitis=NANBH
    ºñAºñB °£¿°
  • non-A, non-B, non-C hepatitis
    ºñA ºñB ºñC °£¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HBsAG hepatitis B surface virus
HBV-MN membranous nephropathy associated with hepatitis B virus
HBVS hepatitis B virus integration site
HeV hepatitis virus
MHV magnetic heart vector; middle hepatic vein; mouse hepatitis virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HBV Hepatitis B virus infection
HCV RNA Hepatitis C virus RNA
HCV Hepatitis C virus infection
HDV Hepatitis D virus
HDV Hepatitis Delta Virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • tobacco mosaic virus
    ´ã¹è ¸ðÀÚÀÌÅ© ¹ÙÀÌ·¯½º
    ´ã¹è³ª Å丶Åä µîÀÇ ÀÙ¿¡ £Àº ³ì»öÀÇ ¹ÝÁ¡ÀÌ »ý±â°Å³ª, ÀÙÀ» ÁÙ¾îµé°Ô ÇÏ´Â ¹Ì»ý¹°. 1892³â D. I. À̹ٳëÇÁ½ºÅ°¿¡ ÀÇÇØ¼­ ÃÖÃÊ·Î ¹ß°ßµÇ¾úÀ¸¸ç, 1935³â W. M. ½ºÅĸ®°¡ ÀÌ ¹ÙÀÌ·¯½º¸¦ ħ»ó °áÁ¤À¸·Î ºÐ¸®ÇÏ´Â µ¥ ¼º°øÇÏ¿´´Ù. ¹ÙÀÌ·¯½º ÀÔÀÚ´Â ±æÀÌ 300 nm, Áö¸§ 15 nmÀÇ À°°¢ÇüÀÇ ¸·´ë ¸ð¾çÀÇ °Å´ë ºÐÀÚÀ̸ç, RNA
  • tomato ringspot virus
    Å丶Åä À±Á¡ ¹ÙÀÌ·¯½º
  • tumor virus
    Á¾¾ç ¹ÙÀÌ·¯½º
  • vacuolated virus
    °øÆ÷¼º ¹ÙÀÌ·¯½º
  • variola major virus
    ´ëµÎâ ¹ÙÀÌ·¯½º
    µÎâÀÇ ÁßÁõÇü ÃâÇ÷¼º µÎâÀ̳ª ¾Ç¼º µÎâ µî »ç¸Á·üÀÌ 25-40À¸·Î ³ôÀº °ÍÀÌ Æ¯Â¡ÀÌ´Ù.
  • variola virus
    ¸¶¸¶ ¹ÙÀÌ·¯½º
  • Venezuelan virus
    º£³×¼ö¿¤¶ó ¹ÙÀÌ·¯½º
    º£³×¼ö¿¤¶ó¿¡¼­ ¸¶³ú¿°À¸·Î Á×Àº µ¿¹°ÀÇ ³ú¿¡¼­ ºÐ¸®µÈ °ÍÀ¸·Î, ¸é¿ªÇÐÀûÀ¸·Î µ¶¸³¼ºÀ» ³ªÅ¸³»¸ç, »ç¶÷¿¡µµ °¨¿°ÇÑ º¸°í°¡ ÀÖ´Ù.
  • verruca virus
    ¿ìÃé ¹ÙÀÌ·¯½º
  • virus
    ¹ÙÀÌ·¯½º
    ¼¼±Õº¸´Ù À۾Ƽ­ ¼¼±Õ ¿©°ú±â·Îµµ ºÐ¸®ÇÒ ¼ö ¾ø°í, ÀüÀÚÇö¹Ì°æÀ» »ç¿ëÇÏÁö ¾ÊÀ¸¸é º¼ ¼ö ¾ø´Â ÀÛÀº ÀÔÀÚ. ºñ·ç½º¶ó°íµµ ÇÑ´Ù. ÀΰøÀûÀÎ ¹èÁö¿¡¼­´Â ¹è¾çÇÒ ¼ö ¾øÁö¸¸ »ì¾Æ ÀÖ´Â ¼¼Æ÷¿¡¼­´Â ¼±ÅÃÀûÀ¸·Î ±âÁõ, Áõ½ÄÇÑ´Ù. ¹ÙÀÌ·¯½º´Â »ýÁ¸¿¡ ÇÊ¿äÇÑ ¹°Áú·Î¼­ ÇÙ»ê
  • virus arthritis
    ¹ÙÀÌ·¯½º °üÀý¿°
  • virus bound antigen
    ¹ÙÀÌ·¯½º °áÇÕ Ç׿ø
  • virus conjunctivitis
    ¹ÙÀÌ·¯½º °á¸·¿°
  • virus culture
    ¹ÙÀÌ·¯½º ¹è¾ç
  • virus disease
    ¹ÙÀÌ·¯½º Áúȯ
    1. ¹ÙÀÌ·¯½º´Â ¼÷ÁÖ¿¡ ħÀÔÇÏ°í ¶ÇÇÑ ¼÷ÁÖ¸¦ ÀÌ¿ëÇÏ¿© Áõ½ÄÇÔÀ¸·Î½á ÁúȯÀ» ÀÏÀ¸Å²´Ù. 2. È£Èí±â, ¼ÒÈ­±â°è, Ç¥ÇÇ-»óÇÇ, Ç츣Æä½º ¹ÙÀÌ·¯½º ÁúȯÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù.
  • virus hemagglutination inhibitor
    ¹ÙÀÌ·¯½º ÀûÇ÷±¸ ÀÀÁý¹ÝÀÀ ¾ïÁ¦ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
hepatitis B <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine.
The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established.
(27 Sep 1997)
hepatitis B antibodies <immunology> Antibodies to the hepatitis b antigens, including antibodies to the surface (Australia) and core of the dane particle and those to the "e" antigens.
(12 Dec 1998)
hepatitis B antigen Antigens of the virion of the hepatitis b virus or the dane particle, its surface, core and other associated antigens, like the hbe antigen.
(12 Dec 1998)
hepatitis b, chronic An inflammatory disease of the liver caused by hepatitis b virus and lasting six months or more.
(12 Dec 1998)
hepatitis B core antigen <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections.
(05 Mar 2000)
hepatitis B e antigen (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious.
(05 Mar 2000)
hepatitis b e antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis b or in virulent chronic hepatitis b, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins g.
(12 Dec 1998)
hepatitis b immunization Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
hepatitis B surface antigen <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test.
(27 Sep 1997)
hepatitis b surface antigens Those hepatitis b antigens found on the surface of the dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
(12 Dec 1998)
hepatitis B vaccine <virology> An injectable vaccine, given in three boosters, which offers protection from infection with hepatitis B.
(27 Sep 1997)
hepatitis b vaccines Vaccines or candidate vaccines containing inactivated hepatitis b or some of its component antigens and designed to prevent hepatitis b. Some vaccines may be recombinantly produced.
(12 Dec 1998)
hepatitis C <virology> A form of viral hepatitis, previously referred to as nonA nonB hepatitis, is the most common form of blood transfusion acquired hepatitis. Transmission through sexual contact is considered rare. Risk factors include recent blood transfusion, IV drug abuse or occupational exposure to blood products. There is no specific treatment. There is a test for hepatitis C antibody which indicates prior exposure. Unlike hepatitis b there is no marker yet identifiable for those who suffer from chronic hepatitis C.
(27 Sep 1997)
hepatitis c antibodies Antibodies to the hepatitis c antigens including antibodies to envelope, core, and non-structural proteins.
(12 Dec 1998)
hepatitis c antigens Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á